重磅盘點!盘點干细胞外泌體在眼科疾病中的研究進展

admin

患者将用人工泪液醫治2周，以創建基線，随後用10g/滴的脐带間充質干细胞外泌體醫治14天，天天4次。疾病指標，如泪液排泄量、泪膜决裂時候和组织毁伤水平，将在醫治後12周內举行记實和评估。

据悉，這是第一個在眼科疾病范畴利用干细胞外泌體的临床實驗。若是樂成，這項钻研預防痘痘,将是一個冲破，并證了然利用干细胞外泌體作為醫治眼病的替换醫治法子的可行性。

小结

干细胞外泌體作為一種新兴的醫治东西，正渐渐在眼科范畴展示出其廣漠的玄關門設計,利用远景。固然今朝仍處于临床钻研阶段，但經由過程不竭的技能前進和临床驗證，干细胞外泌體有望為眼科疾病醫治带来革命性的冲破。咱們等待，将来可以或许看到更多的临床功效，為全世界眼科患者带来新的但愿！

参考文献：失眠貼,

[1] Sanghani A, Andriesei P, Kafetzis KN, Tagalakis AD, Yu-Wai-Man C. Advances in exosome therapies in ophthalmology-From bench to clinical trial. Acta Ophthalmol. 2022 May;100(3):243-252. doi: 10.1111/aos.14932. Epub 2021 Jun 11. PMID: 34114746.

[2] Harrell CR, Djonov V, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Ocular Graft-Versus-Host Disease. Int J Mol Sci. 2022 Oct 31;23(21):13254. doi: 10.3390/ijms232113254. PMID: 36362040; PMCID: PMC9656879.

[3]Harrell CR, Volarevic V, Djonov V, Volarevic A. Therapeutic Potential of Exosomes Derived from Adipose Tissue-Sourced Mesenchymal Stem Cells in the Treatment of Neural金大發娛樂城, and Retinal Diseases. Int J Mol Sci. 2022 Apr 19;23(9):4487. doi: 10.3390/ijms23094487. PMID: 35562878; PMCID: PMC9105552.

[4] Mead B, Amaral J, Tomarev S. Mesenchymal Stem Cell-Derived Small 包皮凝露,Extracellular Vesicles Promote Neuroprotection in Rodent Models of Glaucoma. Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):702-714. doi: 10.1167/iovs.17-22855. PMID: 29392316; PMCID: PMC5795911.

[5皮癬藥膏,] Bai L, Shao H, Wang H, Zhang Z, Su C, Dong L, Yu B, Chen X, Li X, Zhang X. Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoi妹妹une Uveitis. Sci Rep. 2017 Jun 28;7(1):4323. doi: 10.1038/s41598-017-04559-y. Erratum in: Sci Rep. 2018 Jun 26;8(1):9889. doi: 10.1038/s41598-018-28151-0. PMID: 28659587; PMCID: PMC5489510.